In an industrial sector defined mostly by innovation, life sciences research remains a high expense, high-risk scheme – and having a great location strategy is a vital success factor. According [...]
Pfizer is starting out 2019 by tearing up its intermediate-stage and preclinical research and development operations focused on biosimilar drugs, which will cut off hundreds of employees who were [...]